Cotrimoxazole as adjuvant therapy in critical ill COVID 19 patients

Tolazoline as adjuvant therapy for ill neonates with pulmonary hypoperfusion.

Investigation of the smoking prevalence among critically ill patients with COVID-19

In this paper, we investigate the prevalence rate of smoking in COVID-19 patients and examine whether there is a difference in the distribution of smokers between the two statistical populations of critically ill COVID-19 patients and the entire Iranian population or not. To do this, we first prepared a sample of 300 COVID-19 patients admitted to hospitals in Tehran and Rasht. Then, through the...

P159: The Efficacy of Homeopathic Remedies as an Adjuvant Therapy in Patients with Social Phobia

Social phobia is an anxiety disorder characterized by heightened fear and avoidance of one or more social or performance situations, including public speaking, meeting new people, eating or writing in front of others and attending social meetings. People with social phobia are typically anxious about the possibility that others will evaluate them negatively and/or notice symptoms of their anxie...

Cotrimoxazole - optimal dosing in the critically ill

The optimum dosage regimen for cotrimoxazole in the treatment of life threatening infections due to susceptible organisms encountered in critically ill patients is unclear despite decades of the drug's use. Therapeutic drug monitoring to determine the appropriate dosing for successful infection eradication is not widely available. The clinician must utilize published pharmacokinetic, pharmacody...

Insomnia drug therapy in COVID-19 patients; a Letter to Editor

Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the newly emerging SARS-CoV-2 virus that was first reported in December 2019 and was announced as a pandemic disease on March 11th, according to a World Health Organization (WHO) warning (1). SARS-CoV-2 is mainly transmitted through respiratory droplets and close contact, accordingly, requires treatment in isolation. I...